CAMBRIDGE, Mass., July 14, 2026
Apnimed, Inc. has achieved a significant regulatory milestone after the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg), an investigational once-nightly oral therapy for the treatment of adults with obstructive sleep apnea (OSA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027, advancing AD109 toward a potential first-in-class approval. If approved, AD109 could become the first oral pharmacologic therapy specifically designed to target the neuromuscular root cause of upper airway collapse, offering a convenient alternative to existing treatment options such as continuous positive airway pressure (CPAP) devices and surgical interventions. The regulatory acceptance marks an important step in Apnimed’s mission to transform the treatment landscape for one of the world’s most common sleep-related breathing disorders, affecting an estimated 80 million people in the United States and approximately one billion individuals globally.
Phase III Program Demonstrates Strong Clinical Efficacy
The NDA submission is supported by comprehensive clinical evidence from Apnimed’s Phase III development program, including the SynAIRgy and LunAIRo randomized, double-blind, placebo-controlled clinical trials evaluating AD109 in adults with mild, moderate, and severe obstructive sleep apnea. Across both pivotal studies, the investigational therapy achieved statistically significant reductions in the apnea-hypopnea index (AHI), one of the most important clinical measures used to assess sleep apnea severity. The treatment also demonstrated meaningful improvements in oxygenation-related endpoints, including reductions in hypoxic burden and improvements in the oxygen desaturation index (ODI), indicating better nighttime oxygen delivery during sleep. The therapy maintained a generally favorable safety profile, with the most frequently reported adverse events—including dry mouth, insomnia, and nausea—remaining consistent with findings from earlier clinical studies. These positive Phase III data provided the foundation for the FDA’s acceptance of the NDA and support the therapy’s potential to address a significant unmet medical need.
Novel Oral Therapy Targets the Root Cause of OSA
Unlike traditional therapies that primarily manage symptoms by mechanically keeping the airway open, AD109 has been designed to address the underlying neuromuscular dysfunction responsible for upper airway collapse during sleep. The investigational medicine combines aroxybutynin, a novel antimuscarinic agent, with atomoxetine, a selective norepinephrine reuptake inhibitor, creating a unique pharmacological approach intended to improve upper airway muscle tone and maintain normal breathing throughout the night. Administered as a once-nightly oral tablet, AD109 could significantly simplify treatment for patients who struggle with adherence to CPAP therapy or who seek less invasive alternatives. Obstructive sleep apnea is associated with serious long-term complications, including cardiovascular disease, metabolic disorders, neurocognitive impairment, reduced quality of life, and increased mortality, making the availability of effective oral therapies a major objective within sleep medicine.
Advertisement
Regulatory Milestone Signals New Era in Sleep Medicine
The FDA’s acceptance of the AD109 NDA reinforces the growing momentum behind innovative pharmaceutical approaches for treating sleep-related breathing disorders. If approved, AD109 would introduce a new oral treatment paradigm capable of expanding patient access while addressing the limitations associated with device-based therapies. Apnimed believes future management of obstructive sleep apnea will increasingly involve multiple oral therapies targeting different biological mechanisms, enabling more personalized treatment strategies for patients with diverse disease characteristics. As the FDA review progresses toward the February 2027 PDUFA decision, AD109 has the potential to become a transformative therapy that reshapes the management of obstructive sleep apnea by providing a convenient, effective, and non-invasive treatment option capable of improving oxygenation, restorative sleep, and long-term health outcomes for millions of patients worldwide.
Source: Apnimed press release
